Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Candel Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 3 insiders, $3.55M in total
- Insiders trading
- 3
- Net value
- −$3.55M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Candel Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Tak Paul Peter | Chief Executive Officer | 113,321 | Sep 11, 2026 | 2 |
| Zimmermann Martine | Director | – | Sep 10, 2026 | 1 |
| Tyagarajan Seshu | Chief Technology Officer | 76,865 | Aug 19, 2026 | 3 |
| Sims Mark E. | Chief Commercial Officer | – | Jul 8, 2026 | 1 |
| Barone Francesca | Chief Scientific Officer | 77,362 | Jul 1, 2026 | 2 |
| Manning Paul B | Director | 2,763,527Indirect | Jul 1, 2026 | 4 |
| Papa Joseph C | Director | 64,239Indirect | Jul 1, 2026 | 3 |
| Loggia Nicoletta | Director | 2,141 | Jul 1, 2026 | 3 |
| Benz Edward J. JR | Director | – | Jun 24, 2026 | 1 |
| Gaeta Renee | Director | – | Jun 24, 2026 | 1 |
| Nguyen Diem | Director | 10,000 | Jun 24, 2026 | 1 |
| Nabel Gary J. | Director | 5,353 | Jun 24, 2026 | 1 |
| Martell Christopher | Director | 111,349Indirect | Jun 24, 2026 | 1 |
| Radhakrishnan Maha | Director | – | Jun 24, 2026 | 1 |
| Nichols William Garrett | Chief Medical Officer | 52,493 | Jan 28, 2026 | 1 |
| Schoch Charles | Chief Financial Officer | 43,391 | Jan 28, 2026 | 1 |
| Aguilar Laura K. | 10% Owner | 162,929 | Feb 25, 2025 | 0 |
| Aguilar-Cordova Estuardo | 10% Owner | 162,929 | Feb 25, 2025 | 0 |
| Amello Jason | Chief Financial Officer | 202,009 | Nov 30, 2023 | 0 |
| Stewart Susan B. | Chief Regulatory Officer | – | Apr 12, 2022 | 0 |
| Canepa John J | Chief Financial Officer | 10,125 | Mar 1, 2022 | 0 |
| Caffo Nathan | Chief Business Officer | 6,000 | Aug 2, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 2, 2021 (view filing) | Jul 29 | 4 days | Canepa John JChief Financial Officer | PPurchase | +10.1K | $8.00 | +$81.0K | New position10.1K after | |
| Aug 2, 2021 (view filing) | Jul 29 | 4 days | Caffo NathanChief Business Officer | PPurchase | +6.00K | $8.00 | +$48.0K | New position6.00K after | |
| Jul 29, 2021 (view filing) | Jul 27-29 | 2 days | Manning Paul BDirector | PPurchase | +56.0K | $7.34 | +$411.0K | New position56.0K after | 2 lots |